BMY - Bristol-Myers Squibb Co Stock Analysis
Bristol-Myers Squibb Co (BMY) is a publicly traded company listed on the NYSE. It operates in the Drug Manufacturers - General industry, part of the broader Healthcare sector. The company has a market capitalization of 105.76B, generates annual revenue of 48.03B, and reports net income of 6.04B. As of the latest data, the stock is trading at 51.95 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock appears reasonably valued, potentially indicating balanced risk and return. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company is highly leveraged, which may pose risks during economic downturns or periods of rising interest rates. The stock provides a high dividend yield (4.75%), which could indicate strong income potential — or possible risk. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at No Data (None), indicating current market sentiment. Institutional ownership is reported at 81.03%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of -13.33%, trading within a 52-week range of 42.52 - 63.33.
BMY - Bristol-Myers Squibb Co
51.95
Analyst Consensus
No Data None
BMY – Analyst Rating Summary
No analyst data available
No Data
| Index: | S&P 500 | P/E: | 17.54 | EPS (ttm): | 2.96 | Insider Own: | 0.18% | Shs Outstand: | 2.04B | Perf Week: | 5.48% |
| Market Cap: | 105.76B | Forward P/E: | 8.68 | EPS next Y: | 5.99 | Insider Trans: | -1.52% | Shs Float: | 2.03B | Perf Month: | 13.95% |
| Income(ttm): | 6.04B | PEG: | 0.24 | EPS next Q: | 1.61 | Inst Own: | 81.03% | Short Float: | 1.56% | Perf Quarter: | 10.20% |
| Revenue(ttm): | 48.03B | P/S: | 2.20 | EPS this Y: | 465.41% | Inst Trans: | -1.56% | Short Ratio: | 1.99 | Perf Half Y: | 8.59% |
| Book/sh: | 9.11 | P/B: | 5.70 | EPS next Y: | -7.94% | ROA: | 6.34% | Short Interest: | 31.69M | Perf Year: | -13.33% |
| Cash/sh: | 8.11 | P/C: | 6.41 | EPS next 5Y: | 71.99% | ROE: | 33.84% | 52W Range: | 42.52 - 63.33 | Perf YTD: | -8.15% |
| Dividend Est.: | 2.47 (4.75%) | P/FCF: | 6.91 | EPS past 3/5Y: | - - | ROIC: | 9.31% | 52W High: | 63.33 -17.97% | Beta: | 0.30 |
| Dividend TTM: | 2.48 (4.77%) | Quick Ratio: | 1.17 | Sales past 3/5Y: | 1.36% 13.06% | Gross Margin: | 64.33% | 52W Low: | 42.52 22.18% | Perf 5Y: | -17.61% |
| Dividend Ex-Date: | Oct 03, 2025 | Current Ratio: | 1.27 | EPS Y/Y TTM: | 182.66% | Oper. Margin: | 29.18% | RSI (14): | 71.39 | Volatility: | 2.51% 2.48% |
| Employees: | 34100 | Debt/Eq: | 2.75 | Sales Y/Y TTM: | 1.26% | Profit Margin: | 12.57% | Recom: | 2.63 | Target Price: | 52.81 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 2.50 | EPS Q/Q: | 2949.15% | Payout: | - | Rel Volume: | 1.28 | Prev Close: | 50.96 |
| Sales Surprise: | 3.14% | EPS Surprise: | 7.41% | Sales Q/Q: | -0.97% | Earnings: | Oct 30 BMO | Avg Volume: | 15.96M | Price: | 51.95 |
| SMA20: | 8.10% | SMA50: | 13.12% | SMA200: | 5.80% | Overbought: -1.66% | Volume: | 20,461,111 | Change: | 1.94% | |
Graham Classic formula value: 405.29
(P/E=8 * 1g) Min value: 212.61
(current P/E * 2g) Max value: 429.31
Average value: 349.07
About Bristol-Myers Squibb Co
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.